Organization
Celgene Corp.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Celgene Corp.
... Affairs Reputations: Psoriasis (US). Comparing 8 major psoriasis treatments from AbbVie, Amgen, Celgene, Eli Lilly, Janssen Biotech, Pfizer, and Novartis, this report reveals: - How ...
... Multiple Myeloma (US). Comparing 9 major myeloma treatments from AbbVie, Amgen, BMS, Celgene, Janssen Biotech, Novartis, and Takeda, this report reveals: - How oncologists and ...
... genomics. For more information, please visit the company's website at www.agios.com. About Agios/Celgene Collaboration IDHIFA® (enasidenib) and AG-881 are part of Agios' global strategic collaboration ...
... Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a chimeric ...
... F. Hoffmann-La Roche AG, Eli Lilly, Seattle Genetics, Inc., Spectrum Pharmaceuticals, Inc., Celgene Corporation are some notable companies vying for global cancer biological therapy market ...
... milestones since the beginning of the third quarter. Our strategic collaboration with Celgene Corporation has transformed us into a commercial-stage company in China and is ...
... received in July 2016upon the execution of Jounce's global strategic collaboration with Celgene. Research and Development (R&D) Expenses: R&D expenses were $ 17.1 millionfor the ...
... and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, ...
... Important milestone achievements (Kidney disease alliance with Bayer, iPSC neurodegeneration alliance with Celgene, iPSC diabetes alliance with Sanofi) Strong focus on expansion of iPSC platform ...
... milestones since the beginning of the third quarter. Our strategic collaboration with Celgene Corporation has transformed us into a commercial-stage company in China and is ...
... in July 2016 upon the execution of Jounce's global strategic collaboration with Celgene. Research and Development (R&D) Expenses: R&D expenses were $17.1 million for the ...
... Vickers, Ph.D., as CEO. The appointment puts Vickers in charge of the Celgene-partnered biotech as its lead immuno-oncology asset closes in on the start of ...
... veteran Michael Pehl—formerly of Celgene—as its CEO. Pehl was formerly president of Celgene’s hematology and oncology division and will be joined at Immunomedics by former ...
... Canada. Release ​ImmunomedicsMichael Pehl was appointed president and CEO. Michael Pehl joined Celgene in 2006 as the firm’s first Germany GM, and retired as president ...
... Dable, President and Chief Executive Officer of Acceleron. 'We and our partner Celgene continue to invest heavily in our luspatercept development plan with seven clinical ...
... frameworks to ensure that Patient value shapes access." Panelists include: Mark Alles,CEO, Celgene Corporation John Crowley, Chairman of the Board & CEO, Amicus Therapeutics Bob ...
... leader. Most recently, he served as President, Hematology & Oncology, at Celgene Corporation ("Celgene"), and prior to that was the company's Head of Global Marketing, ...
... Important milestone achievements (Kidney disease alliance with Bayer, iPSC neurodegeneration alliance with Celgene, iPSC diabetes alliance with Sanofi) - Strong focus on expansion of iPSC ...
... develop and commercialize a next-generation sequencing (NGS)-based oncology companion diagnostic (CDx) for Celgene's investigational drug CC-122 for indications in Diffuse Large B Cell Lymphoma (DLBCL). ...
... Dable, President and Chief Executive Officer of Acceleron. "We and our partner Celgene continue to invest heavily in our luspatercept development plan with seven clinical ...
... research and development services with TESARO and milestone-related revenues from TESARO and Celgene. The upfront payment was fully recognized and the research and development services ...
... durvalumab in adult r/r aggressive NHL patients, in collaboration with Juno's partner Celgene Corporation. Initiated a clinical trial conducted by the Fred Hutchinson Cancer Research ...
... (MM) patients. While the current range of treatment options - such as Celgene's Revlimid and Takeda's Velcade, and combination regimens of various therapies - are ...
... SUMMIT - Celgene Corporation (NASDAQ: CELG) today announced the successful pricing of three series of ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤